New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage ...

Efforts to improve reporting clinical trial results have led to the development of guidelines such as those recommended by the CONSORT group. 3,4 Transparent and comprehensive reporting of subgroup ...

Delcath Systems announced that subgroup analyses from its phase 3 FOCUS study of the FDA-approved HEPZATO KIT for unresectable metastatic uveal melanoma were published in the Journal of Cancer ...

Delcath Systems (DCTH) announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication was published in the Journal of Cancer Research and Clinical Oncology.

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction ...

Claims of differential treatment effects were largely rated as “low credibility” or “very low credibility.” Subgroup analyses in cancer trials may not be credible, and their results should be ...

Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted in durable complete response (CR) rates across subgroups ...